Clinical Research

Neuro-Ophthalmology

QUARK Study: New Treatment for Acute Non-Arteritic Anterior Ischemic Neuropathy (NAION) exploring treatments for NAION

Investigator: Larry P. Frohman, MD

IIHTT: Idiopathic Intracranial Hypertension Treatment Trial

Investigator: Larry P. Frohman, MD

Sub-Investigator: Roger E. Turbin, MD

Condition:Idiopathic Intracranial Hypertension (also known as Pseudotumor Cerebri)

Status: Active Enrollment

 

Idiopathic intracranial hypertension is a disorder of unknown etiology, predominantly affecting overweight women of childbearing age. The primary problem is chronically elevated intracranial pressure, and the most important neurologic manifestation is papilledema, which may lead to progressive optic atrophy and blindness. The study compares weight-reduction and/or low sodium diet plus acetazolamide (Diamox) with diet plus placebo. This study is being conducted the Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC Network), sponsored by the National Eye Institute..

For more information on the NORDIC study, please contact: Larry P. Frohman, MD at (973) 972-2026, Roger E. Turbin, MD at (973) 972-2209, study coordinator: Amanda Ribeiro, RN at (973) 972-2074.

NAION: A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Investigator: Roger E. Turbin, MD

Sub-Investigator: Larry P. Frohman, MD

Condition:Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Status: Closed to Enrollment

This non-interventional study examines whether the use of phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). This study is sponsored by Pfizer.

For more information on the NAION study, please contact:Roger E. Turbin, MD at (973) 972-2209, Larry P. Frohman, MD at (973) 972-2026, study coordinator:Amanda Ribeiro, RN at (973) 972-2074.

Research Home